Back to top
more

Tabula Rasa Healthcare Inc. (TRHC)

(Delayed Data from NSDQ)

$55.29 USD

55.29
233,468

+2.12 (3.99%)

Updated May 3, 2019 04:00 PM ET

After-Market: $55.17 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Compared to Estimates, Tabula Rasa Healthcare (TRHC) Q2 Earnings: A Look at Key Metrics

by Zacks Equity Research

Although the revenue and EPS for Tabula Rasa Healthcare (TRHC) give a sense of how its business performed in the quarter ended June 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Tabula Rasa Healthcare (TRHC) Q2 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Tabula Rasa Healthcare (TRHC) delivered earnings and revenue surprises of 135.71% and 1.37%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Butterfly Network, Inc. (BFLY) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Butterfly Network, Inc. (BFLY) delivered earnings and revenue surprises of 17.65% and 6.46%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Tabula Rasa Healthcare (TRHC) Moves 6.3% Higher: Will This Strength Last?

by Zacks Equity Research

Tabula Rasa Healthcare (TRHC) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Tabula Rasa Healthcare (TRHC) Surges 7.8%: Is This an Indication of Further Gains?

by Zacks Equity Research

Tabula Rasa Healthcare (TRHC) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Tabula Rasa Healthcare (TRHC) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Tabula Rasa Healthcare (TRHC) delivered earnings and revenue surprises of 86.67% and 5.27%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Will Tabula Rasa Healthcare (TRHC) Report Negative Earnings Next Week? What You Should Know

by Zacks Equity Research

Tabula Rasa Healthcare (TRHC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

NextGen's (NXGN) Behavioral Health Suite Adopted by Mindful Care

by Zacks Equity Research

NextGen's (NXGN) Behavioral Health Suite is expected to facilitate Mindful Care's ability to offer same-day appointments via online scheduling.

NextGen (NXGN) Riding on the Success of Cloud-Based Solution

by Zacks Equity Research

NextGen's (NXGN) cloud-based healthcare technology solutions boost the company's prospect. Strong adoption of its services continues to boost revenues.

Tabula Rasa Healthcare (TRHC) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Tabula Rasa Healthcare (TRHC) delivered earnings and revenue surprises of -200% and 0.22%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Omnicell (OMCL) Q4 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Omnicell (OMCL) delivered earnings and revenue surprises of 266.67% and 3.97%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Tabula Rasa Healthcare (TRHC) to Report Q4 Results: Wall Street Expects Earnings Growth

by Zacks Equity Research

Tabula Rasa Healthcare (TRHC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Inspire Medical Systems (INSP) Beats Q4 Earnings and Revenue Estimates

by Zacks Equity Research

Inspire (INSP) delivered earnings and revenue surprises of 118.52% and 0.14%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Implied Volatility Surging for Tabula Rasa HealthCare (TRHC) Stock Options

by Zacks Equity Research

Investors need to pay close attention to Tabula Rasa HealthCare (TRHC) stock based on the movements in the options market lately.

Tabula Rasa Healthcare (TRHC) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Tabula Rasa Healthcare (TRHC) delivered earnings and revenue surprises of -1,366.67% and 4.64%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

NextGen's (NXGN) Enterprise Adopted by Oak Orchard Health

by Zacks Equity Research

NextGen's (NXGN) EHR and PM solution is expected to aid Oak Orchard Health in improving its workflow.

Do Options Traders Know Something About Tabula Rasa HealthCare (TRHC) Stock We Don't?

by Zacks Equity Research

Investors need to pay close attention to Tabula Rasa HealthCare (TRHC) stock based on the movements in the options market lately.

Here Is Why Bargain Hunters Would Love Fast-paced Mover Tabula Rasa Healthcare (TRHC)

by Zacks Equity Research

Tabula Rasa Healthcare (TRHC) could be a great choice for investors looking to buy stocks that have gained strong momentum recently but are still trading at reasonable prices. It is one of the several stocks that made it through our 'Fast-Paced Momentum at a Bargain' screen.

Does Tabula Rasa Healthcare (TRHC) Have the Potential to Rally 80% as Wall Street Analysts Expect?

by Zacks Equity Research

The mean of analysts' price targets for Tabula Rasa Healthcare (TRHC) points to a 79.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Tabula Rasa Healthcare (TRHC) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Tabula Rasa Healthcare (TRHC) delivered earnings and revenue surprises of -3,300% and 5.93%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Here's Why Tabula Rasa Healthcare (TRHC) Is a Great 'Buy the Bottom' Stock Now

by Zacks Equity Research

After losing some value lately, a hammer chart pattern has been formed for Tabula Rasa Healthcare (TRHC), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.

Analysts Estimate 10x Genomics (TXG) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

10x Genomics (TXG) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Tabula Rasa Healthcare (TRHC) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

by Zacks Equity Research

Tabula Rasa Healthcare (TRHC) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Here Is Why Bargain Hunters Would Love Fast-paced Mover Tabula Rasa Healthcare (TRHC)

by Zacks Equity Research

Tabula Rasa Healthcare (TRHC) could be a great choice for investors looking to buy stocks that have gained strong momentum recently but are still trading at reasonable prices. It is one of the several stocks that made it through our 'Fast-Paced Momentum at a Bargain' screen.

Implied Volatility Surging for Tabula Rasa HealthCare (TRHC) Stock Options

by Zacks Equity Research

Investors need to pay close attention to Tabula Rasa HealthCare (TRHC) stock based on the movements in the options market lately.